Please login to the form below

Not currently logged in
Email:
Password:

UK NHS must change says health chief

The PM Society's annual lecture hears that the UK's National Health Service is not sustainable in its current state

Pharmaceutical companies, the government, primary care trusts (PCTs) and GP consortia need to pull together to tackle the "tsunami" of long-term conditions that the UK health service is facing, the PM Society annual lecture heard.

Sir John Oldham, the Department of Health's national clinical lead for quality and productivity, told guests: "If we continue to manage people with long-term conditions as we do now the NHS is not sustainable. It's not about politics, it's about mathematics.

"We have to make a change. There are ways to treat people with multiple conditions to reduce hospital stays. The pharma industry can help by transferring knowledge to patients so they can co-manage their conditions. We need to shift from a bio-medical model to a social model," he added.

Meanwhile Leslie Galloway, chairman of the Ethical Medicines Industry Group, discussed value based pricing. "Many see it as a threat, but it is not designed to increase prices. We need constant pricing across the UK," he told the guests.

19th May 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics